A RANDOMIZED, DOUBLE BLIND, MULTIPLE DOSING (14 DAYS), PLACEBO-CONTROLLED, INCOMPLETE BLOCK CROSSOVER, MULTI CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF THREE DOSE LEVELS OF AZD7594, GIVEN ONCE DAILY BY INHALATION, IN PATIENTS WITH MILD TO MODERATE ASTHMA
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Velsecorat (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Nov 2015 Planned End Date changed from 1 May 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 13 Nov 2015 Planned primary completion date changed from 1 May 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.